rs505151 — PCSK9 E670G

PCSK9 E670G — The Common Variant That Blunts Your Body's Cholesterol Clearance

PCSK9 (proprotein convertase subtilisin/kexin type 9) is the liver's master regulator of LDL cholesterol — it acts as a molecular brake on the receptors that pull LDL out of the bloodstream. Most well-known PCSK9 variants are rare, gain-of-function mutations¹¹ Most well-known PCSK9 variants are rare, gain-of-function mutations
Rare PCSK9 gain-of-function variants like S127R and D374Y cause familial hypercholesterolemia by driving profound LDLR degradation that dramatically elevate LDL. The E670G variant (rs505151) is different: it is relatively common, sitting at approximately 3-6% minor allele frequency in most populations and approaching 25% in African populations. Studies across multiple cohorts associate the rare G allele with modestly but meaningfully elevated LDL cholesterol and increased coronary artery disease risk.

The Mechanism

PCSK9 is secreted by hepatocytes and binds to the LDL receptor (LDLR) on the cell surface, directing receptor-ligand complexes to lysosomes for degradation rather than recycling. The result: fewer LDL receptors means less LDL cleared from circulation. The E670G variant (Glu670Gly in ancestral protein terms; p.Gly670Glu per HGVS using the GRCh38 reference) sits in exon 12, in the C-terminal domain of PCSK9.

Chen et al. 2005²² Chen et al. 2005
A common PCSK9 haplotype, encompassing the E670G coding SNP, is a novel genetic marker for plasma LDL-C levels and severity of coronary atherosclerosis. JACC, 2005 demonstrated that the G allele operates in a dose-dependent fashion — GG > AG > AA for plasma LDL-C — and accounts for 3.5% of plasma LDL-C variability in the LCAS cohort (F=14.6, p<0.001). The precise structural mechanism has not been definitively characterised; the G allele may subtly alter PCSK9 protein conformation or stability in a way that increases LDLR degradation efficiency. Alternatively, E670G may tag a causal variant elsewhere on the same haplotype through linkage disequilibrium.

Unlike the catastrophic PCSK9 gain-of-function mutations (D374Y, S127R), E670G does not abolish LDLR function — it nudges the cholesterol set point upward by a clinically measurable but individually modest amount.

The Evidence

A 2015 meta-analysis by Cai et al.³³ A 2015 meta-analysis by Cai et al.
The associations between PCSK9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels. Lipids Health Dis, 2015 pooled 17 studies and found that G allele carriers had an OR of 1.546 for CAD in the allelic model (95% CI: 1.301-1.838, p<0.001) and a dominant-model OR of 1.601 (95% CI: 1.314-1.951). LDL-C was significantly elevated in G carriers (standardized mean difference 0.170, 95% CI: 0.053-0.287, p=0.004). This represents the largest systematic synthesis of E670G evidence to date.

Chen et al. JACC 2005⁴⁴ Chen et al. JACC 2005
Chen SN et al. A common PCSK9 haplotype, encompassing the E670G coding SNP, is a novel genetic marker for plasma LDL-C levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005;45(10):1611-9 independently replicated the LDL-C association in 372 LCAS subjects plus a 319-subject validation cohort. Haplotype 3 containing E670G showed significant association with minimum lumen diameter of coronary lesions (OR: 1.83, 95% CI: 1.01-3.55).

In a Tunisian case-control study⁵⁵ Tunisian case-control study
Slimani et al. 2014, Monastir University, n=patients with CHD and ischemic stroke versus healthy controls, the G allele was present in 13.2% of CAD patients versus 6.8% of controls (p=0.030) and 12.2% versus 7.3% in ischemic stroke (p=0.032). G carriers with multi-vessel stenosis had an OR of 3.39 (95% CI: 1.55-7.37), suggesting severity scales with G allele status.

A Chinese cohort study of 778 individuals⁶⁶ Chinese cohort study of 778 individuals
Zhang et al. 2017, 502 CHD patients vs 276 controls; 231 completed statin follow-up found G allele frequency 15.99% in CHD versus 9.34% in controls (OR=1.847, 95% CI: 1.301-2.622). Importantly, after atorvastatin therapy, LDL-C fell significantly more in AA genotype carriers than in AG or GG carriers — G allele carriers showed a blunted statin response, suggesting the E670G-related PCSK9 upregulation partially counteracts statin-driven LDLR induction.

One notable exception: a Taiwanese case-control study⁷⁷ Taiwanese case-control study
Hsu et al. 2009, 202 CAD and 614 controls found G carriers had lower LDL-C in controls after adjustment (2.78 vs 3.02 mmol/L, p=0.029) and no significant CAD association (OR=0.73). This contradictory result likely reflects population-specific LD patterns or confounding, and is an outlier against the weight of evidence from the meta-analysis and larger cohorts.

The large Copenhagen/UK Biobank study by Benn et al. 2019 JACC⁸⁸ Benn et al. 2019 JACC
109,566 individuals with up to 42-year follow-up + 431,043 UK Biobank validation used a weighted allele score across four PCSK9 variants (including E670G) to demonstrate that genetically lower LDL via PCSK9 variation causally reduces cardiovascular mortality (HR 0.79 per 0.5 mmol/L LDL reduction, combined studies p=0.01).

Practical Actions

The G allele at E670G confers a modest but real upward pressure on LDL cholesterol. For heterozygous AG carriers — the most common risk genotype — this typically translates to a few mg/dL of additional LDL-C above the population mean. The actionable implication is proactive LDL monitoring and awareness that standard statin doses may produce smaller reductions than typical. Carriers should know that their PCSK9 activity is slightly elevated, meaning the pharmacological rationale for PCSK9 inhibitors (evolocumab, alirocumab, inclisiran) is biologically stronger for them than for non-carriers, should statin therapy prove insufficient.

For the rare GG homozygotes, the cumulative LDL elevation and CAD risk are more substantial, and aggressive lipid management should be considered sooner rather than waiting for a clinical event.

Interactions

E670G sits in the same biological pathway as the loss-of-function variant rs11591147 (PCSK9 R46L), which confers a 15-47% reduction in coronary disease risk. Individuals carrying both E670G (risk) and R46L (protective) would likely have partially offsetting effects, with the net PCSK9 activity determined by the specific compound. These are different loci and do not represent compound heterozygosity in the classical sense.

The LDLR regulatory variant rs6511720 (T allele) increases LDLR expression by ~29%, which partially counteracts the LDLR degradation driven by elevated PCSK9 activity from the E670G G allele. Individuals carrying the rs505151 G allele alongside the rs6511720 G/G genotype (low LDLR expression) face dual pressure on LDL levels: higher PCSK9 activity degrading receptors, and lower intrinsic receptor expression. Conversely, rs6511720 T carriers partially compensate for E670G risk.

APOE variants (rs429358, rs7412) modulate LDL metabolism through lipoprotein particle composition and receptor binding affinity. APOE4 carriers already have impaired LDLR-mediated clearance, so co-occurrence with E670G G allele represents additive cardiovascular risk.